Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| PDE-I (V for erectile dysfunction, viagra) |
|
|
Term
|
Definition
| Ca Blocker (for Hypertension and Prinzmetal) |
|
|
Term
|
Definition
| Ca Blocker (for HTN and prinzmetal) |
|
|
Term
|
Definition
| Ca Blocker (for HTN and prinzmetal) |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Arterial vasodilator (or rogaine topically); K channel opener |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| Converted to NO; for HTN crisis or CHF; Acts on veins and arteries; Cyanide toxicity (treated with thiosulfate) |
|
|
Term
|
Definition
| Nitroglycerin (coronary arteries and venous vasodilation) |
|
|
Term
|
Definition
| Nitroglycerin (coronary arteries and venous vasodilation) |
|
|
Term
|
Definition
| Nitroglycerin (coronary arteries and venous vasodilation) |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| Diagnose SVT, Potassium efflux causing AV heart block |
|
|
Term
|
Definition
| Suppresses ectopic pacemakers; Exacerbates digoxin toxicity |
|
|
Term
|
Definition
| For Torsades de Pointes, treats digoxin toxicity |
|
|
Term
|
Definition
| Beta Blocker as antiarrhythmics |
|
|
Term
|
Definition
| Beta Blocker as antiarrhythmics |
|
|
Term
|
Definition
| Ca blocker for SVT (like A fib) |
|
|
Term
|
Definition
| Ca blocker for SVT (like A fib) |
|
|
Term
|
Definition
| Class III Antiarrhythmic (blocks K channel); Also Beta blocking activity |
|
|
Term
|
Definition
| Class III Antiarrhythmic (blocks K channel) |
|
|
Term
|
Definition
| Class III Antiarrhythmic (blocks K channel) |
|
|
Term
|
Definition
| Class III Antiarrhythmic (blocks K channel) |
|
|
Term
|
Definition
| Class I-IV antiarrhythmic activity; Alpha and Beta blocking activity; For A or V tachycardias; Side effects: pulmonary fibrosis, hepatotoxicity, thyroid dysfunction (and others) |
|
|
Term
|
Definition
| Class IC Antiarrhythmic (Blocks active Na channel, for SVT, use dependent) |
|
|
Term
|
Definition
| Class IC Antiarrhythmic (Blocks active Na channel, for SVT, use dependent) |
|
|
Term
|
Definition
| Class IC Antiarrhythmic (Blocks active Na channel, for SVT, use dependent) |
|
|
Term
|
Definition
| Class IB Antiarrhythmic (Activated and inactivated Na channel, for VF and VT, use dependent) |
|
|
Term
|
Definition
| Class IB Antiarrhythmic (Activated and inactivated Na channel, for VF and VT, use dependent) |
|
|
Term
|
Definition
| Class IB Antiarrhythmic (Activated and inactivated Na channel, for VF and VT, use dependent) |
|
|
Term
|
Definition
| Class IA Antiarrhythmic (Blocks active Na channel (and somewhat K channel); For AF and VT; Use dependent); Cinchonism |
|
|
Term
|
Definition
| Class IA Antiarrhythmic (Blocks active Na channel (and somewhat K channel); For AF and VT; Use dependent); Drug-induced lupus |
|
|
Term
|
Definition
| Class IA Antiarrhythmic (Blocks active Na channel (and somewhat K channel); For AF and VT; Use dependent); Urinary retention/constipation/double-vision |
|
|
Term
| Treatment for Strep Viridans subacute endocarditis |
|
Definition
|
|
Term
| Treatment for Strep Bovis subacute bacterial endocarditis |
|
Definition
| Penicillin; Also indicates ulcerative colitis or colorectal cancer |
|
|
Term
| Treatment for Staph epidermidis acute endocarditis |
|
Definition
| Vancomycin (Prosthetic valve associated) |
|
|
Term
| Treatment for Staph aureus acute bacterial endocarditis |
|
Definition
| Methicillin (Penicillinase resistant penicillin) or vancomycin (IV Drug user associated) |
|
|
Term
| Treatment for Pseudomonas Aeruginosa acute bacterial endocarditis |
|
Definition
| Penicillin + aminoglycoside (gentamicin); Associated with IV drug userss |
|
|
Term
| Treatment for Cocksackievirus myocarditis |
|
Definition
|
|
Term
| Treatment for pneumococcus lobar typical community aquired pneumonia |
|
Definition
| Penicillin G; Amoxicillin; Cephalosporin (1st generation) |
|
|
Term
| Treatment for p. aeruginosa nosocomial, respirators, CF, pneumonia |
|
Definition
| penicillin (piperacillin or mezlocillin) + aminoglycoside (gentamicin) + Quinolone (ciprofloxacin) or Macrolide (erythromycin) |
|
|
Term
|
Definition
| Isoniazid+rifampin+pyrazinamide (9-12 months) |
|
|
Term
| Treatment for MAC TB in AIDS patients |
|
Definition
| clarithromycin (macrolide) + rifabutin (rifampin) + ethambutol |
|
|
Term
|
Definition
| NA inhibitors (zanamivir, oseltamivir) |
|
|
Term
| Treatment for chlamydophilia pneumoniae atypical pneumonia |
|
Definition
| Doxycycline (tetracycline) |
|
|
Term
| Treatment for chlamydia trachomatis newborn atypical pneumonia |
|
Definition
| erythromycin (aminoglycoside) |
|
|
Term
| Treatment for mycoplasma pneumoniae atypical pneumonia |
|
Definition
|
|
Term
| Treatment for Coxiella Burnetii diseases (atypical pneumonia, myocarditis, granulomatous hepatitis) |
|
Definition
| Doxycycline (tetracycline) |
|
|
Term
| Staph Aureus pneumonia (related to nosocomial, CF, IV drug abuse, abcess formation, etc.) |
|
Definition
| Trimethoprim + sulfamethoxazole |
|
|
Term
| Treatment for Corynebacterium diphtheriae (tonsilitis, grey pseudomembrane, Toxin -> myocarditis) |
|
Definition
|
|
Term
|
Definition
| ciprofloxacin (fluoroquinolone) |
|
|
Term
| Treatment for actinomyces israeli in draining sinus tracts |
|
Definition
|
|
Term
| Treatment for Nocardia asteroides (microabcesses in lung; disseminates) |
|
Definition
| Trimethoprim+sulfamethoxazole |
|
|
Term
| Treatment for whooping cough |
|
Definition
|
|
Term
| Treatment for hemophilus influenzae (epiglottitis, sinusitis, otitis media) |
|
Definition
| Cefotaxime, ceftriaxone (cephalosporins) |
|
|
Term
| Treatment for Moraxella catarrhalis (typical pneumonia, sinusitis, otitis media) |
|
Definition
| Penicillin + clavulanate (Overcomes beta-lactamase resistance for penicillin to work) |
|
|
Term
| Treatment for Klebsiella pneumoniae typical pneumonia (elderly/nosocomial/alcoholics) |
|
Definition
| Ceftriaxone (cephalosporin) |
|
|
Term
| Treatment for legionella pneumophila (severe, dry cough pneumonia; JG apparatus destruction, type IV RTA tubulointerstitial disease) |
|
Definition
| ciprofloxacin (fluoroquinolone) + azithromycin (macrolide) |
|
|
Term
| Treatment for Yersinia pestis (pneumonic type, but known as bubonic plague, rat flea vector, ground squirrels in southwest; large lymph node blisters); |
|
Definition
| gentamicin (aminoglycoside) or doxycycline (tetracycline) |
|
|
Term
| Treatment for cryptococcus neoformans |
|
Definition
|
|
Term
| Treatment for Aspergillus (allergic type, invasive type) |
|
Definition
| Allergic: corticosteroids; Invasive: voriconazole |
|
|
Term
| Treatment for Mucor (Hemorrhagic infacts in lung, frontal lobe invasion, Associated with DKA) |
|
Definition
|
|
Term
| Treatment for dimorphic fungi (Coccidoides, histoplasma, blastomyces) |
|
Definition
|
|
Term
| Prophylactic treatment for AIDS patients against PCP |
|
Definition
| Trimethoprim and sulfamethoxazole |
|
|
Term
|
Definition
| Inhibit PDE (Treatment of asthma, bronchodilation (SM relaxation). |
|
|
Term
|
Definition
| 5-lipooxygenase inhibitor |
|
|
Term
|
Definition
| Inhibit histamine release from mast cells |
|
|
Term
|
Definition
| Reversible leukotriene receptor blocker |
|
|
Term
|
Definition
| leukotriene receptor blocker (reversible) |
|
|
Term
|
Definition
| NE and DA reuptake inhibitors; Block nicotine receptors in brain; smoking cessation |
|
|
Term
|
Definition
| Nicotinic acetylcholine receptor antagonist in brain; smoking cessation |
|
|
Term
|
Definition
| Muscarinic receptor antagonist; COPD and asthma |
|
|
Term
|
Definition
| Beta Agonist; Asthma, hyperkalemia |
|
|
Term
|
Definition
| Beta agonist; asthma and hyperkalemia |
|
|
Term
|
Definition
| Beta agonist; asthma and hyperkalemia |
|
|
Term
|
Definition
| Long acting beta agonist; prevent asthmatic attacts |
|
|
Term
|
Definition
| Beta agonist; treats bronchospasm in asthma attack |
|
|
Term
|
Definition
| Muscarinic receptor antagonist; Asthma and COPD |
|
|
Term
|
Definition
| M3 receptor antagonist; Urinary incontinence |
|
|
Term
|
Definition
| M1-3 receptor antagonist; Urinary incontinence |
|
|
Term
|
Definition
| Inhaled glucocorticoid; chronic asthma treatment; minimal side effects |
|
|
Term
|
Definition
| Thienopyridine; Platelet aggregation inhibitor (P2Y receptor antagonist, inhibits ADP pathway); Acute coronary event and w/ stent placement |
|
|
Term
|
Definition
| Thienopyridine; Platelet aggregation inhibitor (P2Y antagonist, inhibits ADP pathway); Acute coronary syndrome and pre-stent |
|
|
Term
|
Definition
| Inhibits PDE in platelets, Decreased TXA2 synthesis shifting balance towards prostacyclin and away from TXA2; Stroke prevention and cardiac stress test |
|
|
Term
|
Definition
| Aspirin; Irreversibly binds COX1/2 |
|
|
Term
|
Definition
| Direct thrombin inhibitor; for patients that cannot take heparin |
|
|
Term
|
Definition
| Direct thrombin inhibitor; for patients that cannot take heparin |
|
|
Term
|
Definition
| Direct thrombin inhibitor; for patients that cannot take heparin |
|
|
Term
|
Definition
| Direct thrombin inhibitor; for patients that cannot take heparin |
|
|
Term
|
Definition
| Direct thrombin inhibitor; for patients that cannot take heparin |
|
|
Term
|
Definition
| Direct thrombin inhibitor; for patients that cannot take heparin |
|
|
Term
|
Definition
| Direct thrombin inhibitor; for patients that cannot take heparin |
|
|
Term
|
Definition
| Warfarin; Inhibits vit K dependent thrombogenic factors in liver; Chronic anticoagulation (e.g. AF) |
|
|
Term
|
Definition
| Heparin; Increases antithrombin III action (degrades factor X); For DVTs, pulmonary embolisms, MI |
|
|
Term
|
Definition
| Heparin; Increases antithrombin III action (degrades factor X); For DVTs, pulmonary embolisms, MI |
|
|
Term
|
Definition
| Converts Plasminogen to plasmin; Fibrinolytic agent |
|
|
Term
|
Definition
| Converts Plasminogen to plasmin; Fibrinolytic agent |
|
|
Term
|
Definition
| Converts Plasminogen to plasmin; Fibrinolytic agent |
|
|
Term
|
Definition
| Converts Plasminogen to plasmin; Fibrinolytic agent |
|
|
Term
|
Definition
| Converts Plasminogen to plasmin; Fibrinolytic agent |
|
|
Term
|
Definition
| GPIIb/IIIa receptor blocker on platelets; Acute coronary syndrome and w/ PCI |
|
|
Term
|
Definition
| GPIIb/IIIa receptor blocker on platelets; Acute coronary syndrome and w/ PCI |
|
|
Term
|
Definition
| GPIIb/IIIa receptor blocker on platelets; Acute coronary syndrome and w/ PCI |
|
|
Term
|
Definition
| Alpha-2 agonist (in medulla, decreases NE release, vasodilation w/ decreased CO); For hypertension |
|
|
Term
|
Definition
| B-agonist (; For Torsades de Pointes, cardiac arrest, heart block; |
|
|
Term
|
Definition
| D1 receptor agonist (splanchnic and renal vasodilation); For severe HTN |
|
|
Term
|
Definition
| Alpha-2 agonist; Acts on brain to increase catecholamines, Increase in CO but larger decrease in vasodilation; For HTN |
|
|
Term
|
Definition
| Alpha-2 agonist (In medulla, decreased NE release, peripheral vasodilation, decreased CO); for HTN |
|
|
Term
|
Definition
| Alpha-1 agonist (systemic vasoconstriction); For shock |
|
|
Term
|
Definition
| Alpha-1 agonist; For hepatorenal syndrome |
|
|
Term
|
Definition
| Alpha-1 agonist; peripheral vasoconstriction; For shock |
|
|
Term
|
Definition
| Beta-1 agonist; Increases CO; for CHF and cardiogenic shock |
|
|
Term
|
Definition
| Alpha and Beta-1 agonist; For shock |
|
|
Term
|
Definition
| Alpha and Beta agonist; Severe hypotension |
|
|
Term
|
Definition
| Beta blocker (Decreased CO, Decreased BP, bronchoconstriction); for HTN, CAD |
|
|
Term
|
Definition
| Beta blocker (Decreased CO, Decreased BP, bronchoconstriction); for HTN, CAD |
|
|
Term
|
Definition
| Beta blocker (Decreased CO, Decreased BP, bronchoconstriction); for HTN, CAD |
|
|
Term
|
Definition
| Beta blocker (Decreased CO, Decreased BP, bronchoconstriction); for HTN, CAD |
|
|
Term
|
Definition
| Beta blocker and alpha-1 blocker; CHF and HTN |
|
|
Term
|
Definition
| Beta blocker and alpha-1 blocker; CHF and HTN |
|
|
Term
|
Definition
| Inhibits pancreatic lipase; Decreases fat absorption; Antiobesity |
|
|
Term
|
Definition
| Fibrates; Stimulates Lipoprotein Lipase; Used to decrease cholesterol and triglycerides |
|
|
Term
|
Definition
| Fibrates; Stimulates Lipoprotein Lipase; Used to decrease cholesterol and triglycerides |
|
|
Term
|
Definition
| Fibrates; Stimulates Lipoprotein Lipase; Used to decrease cholesterol and triglycerides |
|
|
Term
|
Definition
| Fibrates; Stimulates Lipoprotein Lipase; Used to decrease cholesterol and triglycerides |
|
|
Term
|
Definition
| Decreasing adipose lipolysis; Increase HDL and decrease LDL; (flushing) |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| HMG-CoA reductase inhibitor |
|
|
Term
|
Definition
| HMG-CoA reductase inhibitor |
|
|
Term
|
Definition
| HMG-CoA reductase inhibitor |
|
|
Term
|
Definition
| HMG-CoA reductase inhibitor |
|
|
Term
|
Definition
| HMG-CoA reductase inhibitor |
|
|
Term
|
Definition
| HMG-CoA reductase inhibitor |
|
|
Term
|
Definition
| Decreases LDL levels by decreasing cholesterol reabsorption in GI tract |
|
|
Term
|
Definition
| Trimethoprim-sulamethoxalone |
|
|
Term
|
Definition
| Phosphate Binding Resin (for CRF) |
|
|
Term
| Treatment for Malignant HTN |
|
Definition
|
|
Term
| Treatment for Pyelonephritis |
|
Definition
| Ciprofloxacin (fluoroquinolone) |
|
|
Term
|
Definition
| Xanthine Oxidase Inhibitor (gout, tumor lysis syndrome) |
|
|
Term
|
Definition
| Microtubular depolymerization; (gout) |
|
|
Term
|
Definition
| Decreases uric acid reabsorption in prox. tub. of kidney (Gout) |
|
|
Term
|
Definition
| Androgen receptor antagonist (prostate cancer, given with Leuprolide) |
|
|
Term
|
Definition
| 5-alpha reductase inhibitor; (BPH and prostate cancer) |
|
|
Term
|
Definition
| V1 agonist (vasoconstriction); V2 agonist (Increase water reabsorption); For central DI, septic/cardiogenic shock |
|
|
Term
|
Definition
| V1 agonist (vasoconstriction); V2 agonist (Increase water reabsorption); For central DI, septic/cardiogenic shock |
|
|
Term
|
Definition
| Alpha-1 antagonist (decrease BP); For HTN |
|
|
Term
|
Definition
| Alpha-1 antagonist (Decrease bladder neck contraction); For BPH, HTN |
|
|
Term
|
Definition
| Alpha-1 antagonist (Decrease bladder neck contraction); For BPH |
|
|
Term
|
Definition
| Alpha-1 antagonist (Decrease bladder neck contraction); For BPH |
|
|
